What is the price target for BBNX stock?
17 analysts have analysed BBNX and the average price target is 23.83 USD. This implies a price increase of 119.24% is expected in the next year compared to the current price of 10.87.
NASDAQ:BBNX • US08659B1026
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BETA BIONICS INC (BBNX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-18 | Stifel | Maintains | Buy -> Buy |
| 2026-02-18 | Baird | Maintains | Neutral -> Neutral |
| 2026-02-04 | Stifel | Maintains | Buy -> Buy |
| 2026-02-02 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-27 | TD Cowen | Initiate | Hold |
| 2026-01-09 | Lake Street | Maintains | Buy -> Buy |
| 2026-01-05 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-18 | Truist Securities | Maintains | Buy -> Buy |
| 2025-10-29 | Stifel | Reiterate | Buy -> Buy |
| 2025-10-29 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-29 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-10-21 | Stifel | Reiterate | Buy |
| 2025-10-01 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2025-09-22 | Truist Securities | Maintains | Buy -> Buy |
| 2025-07-30 | Truist Securities | Maintains | Buy -> Buy |
| 2025-07-30 | Baird | Maintains | Neutral -> Neutral |
| 2025-06-16 | Truist Securities | Initiate | Buy |
| 2025-05-30 | Wolfe Research | Initiate | Outperform |
| 2025-05-30 | Goldman Sachs | Initiate | Neutral |
| 2025-02-24 | Leerink Partners | Initiate | Outperform |
| 2025-02-24 | Lake Street | Initiate | Buy |
| 2025-02-24 | Stifel | Initiate | Buy |
| 2025-02-24 | Piper Sandler | Initiate | Overweight |
| 2025-02-20 | Ladenburg Thalmann | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 11.995M 6,601.12% | 65.124M 442.93% | 100.251M 53.94% | 135.33M 34.99% | 181.98M 34.47% | 255.3M 40.29% | 357.05M 39.86% | 460.07M 28.85% | 517.14M 12.40% | 634.44M 22.68% | |
| EBITDA YoY % growth | -34.624M 46.32% | -44.1M -27.37% | -70.108M -58.98% | -71.555M -2.06% | -69.372M 3.05% | -42.088M 39.33% | -33.15M 21.24% | -10.608M 68.00% | N/A | N/A | |
| EBIT YoY % growth | -35.85M 45.55% | -45.251M -26.22% | -71.681M -58.41% | -98.423M -37.31% | -99.754M -1.35% | -81.245M 18.56% | -60.18M 25.93% | -25.5M 57.63% | 52.02M 304.00% | 68.34M 31.37% | |
| Operating Margin | -298.87% | -69.48% | -71.50% | -72.73% | -54.82% | -31.82% | -16.85% | -5.54% | 10.06% | 10.77% | |
| EPS YoY % growth | N/A | N/A | -1.94 8.78% | -1.95 -0.29% | -1.95 -0.44% | -1.33 31.77% | -1.93 -44.59% | -1.51 21.69% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.48 47.99% | -0.50 -27.87% | -0.42 -28.10% | -0.44 -51.74% | -0.48 0.88% | -0.44 12.73% | -0.39 8.31% | -0.41 6.51% |
| Revenue Q2Q % growth | 27.443M 55.58% | 32.174M 38.45% | 35.491M 30.23% | 40.01M 24.56% | 38.624M 40.74% | 41.721M 29.67% | 45.801M 29.05% | 53.424M 33.53% |
| EBITDA Q2Q % growth | -19.461M -6.12% | -18.824M 2.07% | -14.608M 8.75% | -15.573M -7.02% | -15.69M 19.38% | -14.618M 22.35% | -14.547M 0.42% | -15.958M -2.47% |
| EBIT Q2Q % growth | -24.808M -33.08% | -25.277M -27.20% | -20.981M -23.10% | -21.705M -34.61% | -22.511M 9.26% | -20.809M 17.68% | -18.638M 11.17% | -19.587M 9.76% |
All data in USD
17 analysts have analysed BBNX and the average price target is 23.83 USD. This implies a price increase of 119.24% is expected in the next year compared to the current price of 10.87.
BETA BIONICS INC (BBNX) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of BETA BIONICS INC (BBNX) is -0.48 USD and the consensus revenue estimate is 27.44M USD.
The number of analysts covering BETA BIONICS INC (BBNX) is 17.